Nimbus Therapeutics said on Tuesday it has entered into a multi-year research and licensing agreement with Eli Lilly to ...

Drugmaker Novo Nordisk said the prescription medicine can be found at a range of pharmacies, including CVS and Costco, as ...

Adding high‑intensity interval training to a lifestyle intervention enhances short‑term physical activity in children and ...

A new definition of obesity could nearly double the prevalence of U.S. adults with the condition, a new study published ...

Arrowhead Pharmaceuticals has reported early-phase data on a pair of gene silencing drug candidates in obesity, posting ...

Eli Lilly and Nimbus Therapeutics have entered into a multiyear collaboration and exclusive licensing agreement to develop an ...

Eli Lilly has returned to Nimbus Therapeutics for another metabolic collaboration, this time focused on the red-hot R&D space ...

Nimbus will apply its computational chemistry and structure-based drug design to a discovery programme in obesity treatment.

Arrowhead Pharmaceutical’s investigational RNA interference (RNAi) obesity candidate in combination with Eli Lilly’s Zepbound (tirzepatide) has shown benefit in interim data from a Phase I/IIa trial.

"Food noise" is the buzz in the battle against obesity. GLP1 injectables don't just decrease appetite, but also quiet "food ...

Americans can now purchase a starter dose of Novo Nordisk’s weight loss drug Wegovy in pill form, the company announced ...

Eli Lilly & Co slashed the price of its blockbuster weight-loss and diabetes drug Mounjaro in China, intensifying competition ...